Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International Inc (NASDAQ: DYAI) delivers innovative biotechnological solutions through its proprietary C1 and Dapibus™ platforms, serving pharmaceutical developers and industrial partners worldwide. This news hub provides investors and industry professionals with timely updates on strategic developments, financial milestones, and scientific advancements.
Access consolidated information on DYAI's licensing agreements, product pipeline progress, and operational updates. Our repository includes press releases covering clinical collaborations, manufacturing expansions, and technology applications across vaccine development, therapeutic proteins, and sustainable food production sectors.
Key updates include earnings announcements, partnership disclosures with leading biopharma entities, regulatory filings, and platform efficiency improvements. Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis.
Dyadic International (NASDAQ: DYAI) has engineered its C1-cells to produce therapeutically viable cannabis compounds, including cannabidiol (CBD), enhancing production efficiency. This innovative approach could lower costs and improve product purity compared to traditional extraction from Cannabis sativa. The company emphasizes environmental benefits and potential medical applications of cannabinoids, such as therapeutic effects on inflammation and viral infections like coronavirus. Dyadic aims to leverage this technology as part of a broader strategic plan focusing on human and animal health.
Dyadic International, Inc. (NASDAQ: DYAI) has been awarded a project grant of up to $690,000 from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) through the American Rescue Plan. This funding aims to enhance Dyadic's proprietary C1 thermophilic fungal protein production platform to develop antibodies. The project will benchmark the platform's speed compared to traditional methods, aiming to improve public health responses to future pandemics.
Dyadic International (NASDAQ: DYAI) announced a strategic collaboration with Janssen Biotech to utilize its C1-cell protein production platform. Janssen will pay Dyadic an upfront fee of $500,000 and provide up to €1.6 million for R&D. The agreement includes potential mid-seven figure payments for exclusive licenses and additional milestone payments based on product development. This partnership aims to enhance therapeutic protein development, showcasing Dyadic's expanding role in biopharmaceuticals.
Dyadic International (NASDAQ: DYAI) advances its COVID-19 vaccine candidate, DYAI-100, towards first-in-human trials. The company reported $22.8 million in cash as of September 30, 2021, down from $29.2 million at year-end 2020. R&D revenue rose to $693,000, while R&D expenses surged to $1.9 million for Q3 2021, driven by the clinical trial costs for DYAI-100. Dyadic has also engaged in new R&D collaborations and enhanced its leadership team with the appointment of Joseph Hazelton as Chief Business Officer. The net loss narrowed to $1.7 million, or $(0.06) per share.
Dyadic International has appointed Joe Hazelton as Chief Business Officer, effective immediately, to enhance global commercialization of its C1-cell protein production platform. This strategic move aims to support new and existing business initiatives, including corporate strategy and licensing. Mr. Hazelton, with over 20 years in the pharmaceutical industry, will lead efforts to maximize the integration of the C1 technology across various sectors, targeting the expanding biologic markets and animal health segments.
Dyadic International will report its Q3 2021 financial results on November 10, 2021. The company focuses on its proprietary C1-cell protein production platform aimed at enhancing biologic vaccine and drug development. This platform is designed to lower production costs and improve performance. Investors can join a conference call at 5:00 PM ET to discuss these results and the company's future outlook. The C1 technology utilizes the fungus Thermothelomyces heterothallica to produce low-cost proteins efficiently.
Dyadic International (NASDAQ:DYAI) has announced its participation in a virtual investor event on September 13, 2021, presenting at 7 AM ET. Mark Emalfarb, the CEO, will discuss the company's proprietary C1-cell protein production platform aimed at enhancing the development and manufacturing of biologic vaccines and therapeutics. This platform promises to accelerate production, reduce costs, and improve performance, addressing the growing demand for biologics. The conference runs until September 15, 2021, with on-demand access available.
Dyadic International announced a binding term sheet with Sorrento Therapeutics to outlicense its C1 protein production platform for developing vaccines and therapeutics targeting coronaviruses, including its lead candidate DYAI-100. The partnership is expected to generate $10 million upfront and potential milestone payments up to $33 million. The company reported a 66.5% revenue increase year over year and held $25.8 million in cash and securities as of June 30, 2021. Dyadic is advancing its COVID-19 vaccine candidate toward Phase 1 trials, benefiting from new collaborations with Syngene International and the Rubic Consortium.
Dyadic International has signed a binding term sheet with Sorrento Therapeutics granting exclusive rights to utilize its C1 technology across multiple regions for developing vaccines, therapeutics, and diagnostics for coronaviruses, including the lead vaccine candidate DYAI-100. The agreement entails a $10 million upfront payment, potential future milestone payments, and ongoing royalties. This partnership aims to enhance Sorrento's COVID-19 programs and address global immunization needs effectively.
Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its financial results for the second quarter of 2021 on August 12, 2021. The company aims to leverage its proprietary C1-cell protein production platform to enhance the development and production of biologic vaccines and drugs. A conference call will occur at 5:00 p.m. ET, providing investors access to discuss the financial results and company updates.
Interested parties can access the live webcast and replay via designated links provided in the announcement.
